This is true. In the biotech space the success of one company helps all other companies in the sector. Unfortunately, the reverse is also true.
I should mention that FTO is important in GBM. I would expect that there is a reasonable possibility that it would be synergistic with CAR-T treatments for this cancer type. Of course the only way to find out is run trials, but we already know that bisantrene is effective against GBM in vitro as a low dose FTO targeted agent.
- Forums
- ASX - By Stock
- RAC
- Ann: Appendix 3Y - Dr Daniel Tillett
Ann: Appendix 3Y - Dr Daniel Tillett, page-44
-
-
- There are more pages in this discussion • 71 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.66 |
Change
0.000(0.00%) |
Mkt cap ! $280.3M |
Open | High | Low | Value | Volume |
$1.68 | $1.68 | $1.62 | $102.7K | 62.79K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 359 | $1.65 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.66 | 249 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 359 | 1.645 |
1 | 48323 | 1.640 |
1 | 10000 | 1.615 |
1 | 19208 | 1.610 |
3 | 20625 | 1.600 |
Price($) | Vol. | No. |
---|---|---|
1.660 | 250 | 1 |
1.680 | 5000 | 1 |
1.720 | 580 | 1 |
1.730 | 26101 | 2 |
1.750 | 508 | 1 |
Last trade - 16.10pm 05/09/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |